Lampalizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lampalizumab
Monoclonal antibody
Type Fab fragment
Source Humanized (from mouse)
Target CFD
Clinical data
Routes of
administration
Intravitreal
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C2068H3214N546O676S13
Molar mass 46.96 kg/mol

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.[1][2]

One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.[4]

These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.[5]

References[edit]

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
  3. ^ "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration". www.roche.com. Retrieved 2017-09-14.
  4. ^ "Statement on Chroma Study". www.roche.com. Retrieved 2017-11-10.
  5. ^ Dolgin, E (9 November 2017). "Age-related macular degeneration foils drugmakers". Nature Biotechnology. 35 (11): 1000–1001. doi:10.1038/nbt1117-1000. PMID 29121027.